ImmunoGen, Inc.  

(Public, NASDAQ:IMGN)   Watch this stock  
+0.11 (6.21%)
Dec 2 - Close
NASDAQ real-time data - Disclaimer
Currency in USD
Range 1.78 - 1.94
52 week 1.51 - 14.10
Open 1.78
Vol / Avg. 1.07M/1.40M
Mkt cap 173.35M
P/E     -
Div/yield     -
EPS -1.79
Shares 87.30M
Beta 2.04
Inst. own 87%
Jan 27, 2017
Q2 2017 ImmunoGen Inc Earnings Release (Estimated) - 6:30AM EST - Add to calendar
Dec 9, 2016
ImmunoGen Inc Annual Shareholders Meeting - 11:00AM EST - Add to calendar
Nov 9, 2016
Immunogen Inc Annual Shareholders Meeting (Estimated)
Oct 28, 2016
Q1 2017 ImmunoGen Inc Earnings Call - Webcast
Oct 28, 2016
Q1 2017 ImmunoGen Inc Earnings Release
Sep 29, 2016
ImmunoGen Inc Completes Strategic Review To Strengthen The Organization And Drive Long-Term Growth - Webcast
Sep 12, 2016
ImmunoGen Inc at Morgan Stanley Global Healthcare Conference - Webcast
More events from DailyFinance »    

Key stats and ratios

Q3 (Sep '16) 2016
Net profit margin -583.96% -241.35%
Operating margin -507.02% -208.31%
EBITD margin - -199.43%
Return on average assets -70.28% -48.84%
Return on average equity - -
Employees 385 -
CDP Score - -


WALTHAM, MA 02451-1477
United States - Map
+1-781-8950600 (Phone)
+1-781-8950611 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money


ImmunoGen, Inc. is a clinical-stage biotechnology company that develops targeted cancer therapeutics using its antibody-drug conjugate (ADC) technology. The Company is engaged in the discovery of monoclonal antibody-based anticancer therapeutics. An ADC with the Company's technology comprises an antibody that binds to a target found on tumor cells conjugated to one of its anti-cancer agents as a payload to kill the tumor cell once the ADC has bound to its target. Its product candidates include Mirvetuximab soravtansine; IMGN779; IMGN632; IMGN529, and Coltuximab ravtansine. Its portfolio is led by Mirvetuximab soravtansine, a first-in-class ADC targeting folate-receptor alpha (Fra). Its FORWARD II consists of cohorts assessing Mirvetuximab soravtansine in combination with, in separate doublets, Avastin (bevacizumab), pegylated liposomal doxorubicin (PLD), and carboplatin. The Company has developed tubulin-acting maytansinoid payload agents, which include DM1 and DM4.

Officers and directors

Stephen C. McCluski Independent Chairman of the Board
Age: 64
Bio & Compensation  - Reuters
Mark J. Enyedy President, Chief Executive Officer, Director
Age: 52
Bio & Compensation  - Reuters
David B Johnston PhD Chief Financial Officer, Executive Vice President
Bio & Compensation  - Reuters
Ellie Harrison Chief Human Resource Officer, Vice President
Age: 60
Bio & Compensation  - Reuters
Richard J. Gregory Ph.D. Executive Vice President - Research, Chief Scientific Officer
Age: 58
Bio & Compensation  - Reuters
John M. Lambert Ph.D. Executive Vice President - Distinguished Research Fellow
Age: 64
Bio & Compensation  - Reuters
Sandra E. Poole Senior Vice President - Technical Operations.
Age: 51
Bio & Compensation  - Reuters
Craig Barrows Vice President, General Counsel, Secretary
Age: 60
Bio & Compensation  - Reuters
Anna Berkenblit M.D. Vice President and Chief Medical Officer
Bio & Compensation  - Reuters
Peter J. Williams Vice President - Business Development
Age: 61
Bio & Compensation  - Reuters